New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2014
08:05 EDTMDVNMedivation price target raised to $95 from $80 at Credit Suisse
Credit Suisse raised Medvation's price target ahead of PREVAIL trial data on January 30. The firm has increased confidence in the data and raised 2015 and beyond estimates. Shares are Outperform rated.
News For MDVN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 24, 2014
09:59 EDTMDVNOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:31 EDTMDVNMedivation downgraded to Neutral from Buy at Goldman
Goldman Sachs downgraded Medivation to Neutral saying current share levels fairly value Xtandi's opportunities in prostate and breast cancer. Goldman raised its price target for shares to $110 from $90 and believes Medivation's fundamentals remain strong.
September 18, 2014
10:00 EDTMDVNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:47 EDTMDVNMedivation upgraded to Buy at Canaccord
As reported previously, Canaccord upgraded Medivation to Buy from Hold citing the pre-chemotherapy opportunity and meaningful incremental share gains of its Xtandi drug. Canaccord raised its price target on Medivation to $132 from $60.
06:13 EDTMDVNMedivation upgraded to Buy from Hold at Canaccord
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use